Treatment for Heart Failure

N/A

Recruiting

Research Sponsored by CVRx, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 36 months post-implant

Awards & highlights

Summary

The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 36 months post-implant

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~36 months post-implant

This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months post-implant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of serious adverse events related to the system or implant procedure

Secondary outcome measures

Change NYHA Classification

Change in LVEF

Change in NT-proBNP

+3 more

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

CVRx, Inc.Lead Sponsor

20 Previous Clinical Trials

3,531 Total Patients Enrolled

11 Trials studying Heart Failure

2,252 Patients Enrolled for Heart Failure

Thomas DeeringStudy ChairPiedmont Heart Institute

Bradley KnightStudy ChairNorthwestern Medicine

~2316 spots leftby Jun 2028

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.